Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy

被引：13
|
作者：
Zenke, Frank T. [1 ]
Zimmermann, Astrid [1 ]
Dahmen, Heike [1 ]
Elenbaas, Brian [2 ]
Pollard, John [3 ]
Reaper, Philip [3 ]
Bagrodia, S. [4 ]
Spilker, M. E. [4 ]
Amendt, C. [1 ]
Blaukat, Andree [1 ]
机构：
[1] Merck KGaA, Darmstadt, Germany
[2] EMD Serono, Billerica, MA USA
[3] Vedex Pharmaceut Ltd, Abingdon, Oxon, England
[4] Pfizer Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-369
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity
    Bonday, Zahid Q.
    Cortez, Guillermo S.
    Grogan, Michael J.
    Antonysamy, Stephen
    Weichert, Ken
    Bocchinfuso, Wayne P.
    Li, Fengling
    Kennedy, Steven
    Li, Binghui
    Mader, Mary M.
    Arrowsmith, Cheryl H.
    Brown, Peter J.
    Eram, Mohammad S.
    Szewczyk, Magdalena M.
    Barsyte-Lovejoy, Dalia
    Vedadi, Masoud
    Guccione, Ernesto
    Campbell, Robert M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 612 - 617
  • [42] Biological characterization of ETP-46321 a potent and selective phosphoinositide-3-kinase inhibitor with antitumor activity
    Bischoff, J. R.
    Pastor, J.
    Cebrian, D.
    Martinez, S.
    Lorenzo, M.
    Merino, T.
    Fominaya, J.
    Pizcueta, P.
    Rodriguez Lopez, A.
    Granda, T. G.
    EJC SUPPLEMENTS, 2010, 8 (07): : 49 - 49
  • [43] Activity of the HDAC inhibitor, PXD101, used as monotherapy and combination therapy in preclinical NSCLC studies
    Qian, Xiaozhong
    Larochelle, William J.
    Ara, Gulshan
    Sehested, Maxwell
    Lichestein, Henri S.
    Jeffers, Michael
    CANCER RESEARCH, 2006, 66 (08)
  • [44] AZD7648: A potent and selective inhibitor of DNA-PK with pharmacodynamic and monotherapy anti-tumor activity
    Cadogan, Elaine B.
    Fok, Jacqueline H.
    Ramos-Montoya, Antonio
    James, Neil
    Follia, Valeria
    Vazquez-Chantada, Mercedes
    Winjhoven, Paul
    O'Connor, Lenka Oplustil
    Karmokar, Ankur
    Staniszewska, Anna
    Dean, Emma
    Hollingsworth, Simon J.
    Davies, Barry
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Activity of PARP1-selective inhibitor SNV-001 in models of HRD cancers as monotherapy and in combination
    Li, Zhentian
    Fan, Qipeng
    Gao, Mingming
    Pan, Jun
    Wu, Liangxing
    Yao, Wenqing
    Liu, Phillip C.
    CANCER RESEARCH, 2023, 84 (06)
  • [46] A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature
    Kemble, Alicia M.
    Hornsperger, Benoit
    Ruf, Iris
    Richter, Hans
    Benz, Jorg
    Kuhn, Bernd
    Heer, Dominik
    Wittwer, Matthias
    Engelhardt, Britta
    Grether, Uwe
    Collin, Ludovic
    PLOS ONE, 2022, 17 (09):
  • [47] Polymer micelle-based combination therapy of paclitaxel and resveratrol with enhanced and selective antitumor activity
    Hu, Mengying
    Zhu, Jinfang
    Qiu, Liyan
    RSC ADVANCES, 2014, 4 (109): : 64151 - 64161
  • [48] Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity
    Ott, Gregory R.
    Tripathy, Rabindranath
    Cheng, Mangeng
    McHugh, Robert
    Anzalone, Andrew V.
    Underiner, Ted L.
    Curry, Matthew A.
    Quail, Matthew R.
    Lu, Lihui
    Wan, Weihua
    Angeles, Thelma S.
    Albom, Mark S.
    Aimone, Lisa D.
    Ator, Mark A.
    Ruggeri, Bruce A.
    Dorsey, Bruce D.
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 493 - 498
  • [49] Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
    Shen, Ke
    Yang, Li
    Li, Fei-Yan
    Zhang, Feng
    Ding, Lei-Lei
    Yang, Jing
    Lu, Jie
    Wang, Nan-Nan
    Wang, Yan
    CURRENT DRUG TARGETS, 2022, 23 (02) : 145 - 155
  • [50] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
    Souers, Andrew J.
    Leverson, Joel D.
    Boghaert, Erwin R.
    Ackler, Scott L.
    Catron, Nathaniel D.
    Chen, Jun
    Dayton, Brian D.
    Ding, Hong
    Enschede, Sari H.
    Fairbrother, Wayne J.
    Huang, David C. S.
    Hymowitz, Sarah G.
    Jin, Sha
    Khaw, Seong Lin
    Kovar, Peter J.
    Lam, Lloyd T.
    Lee, Jackie
    Maecker, Heather L.
    Marsh, Kennan C.
    Mason, Kylie D.
    Mitten, Michael J.
    Nimmer, Paul M.
    Oleksijew, Anatol
    Park, Chang H.
    Park, Cheol-Min
    Phillips, Darren C.
    Roberts, Andrew W.
    Sampath, Deepak
    Seymour, John F.
    Smith, Morey L.
    Sullivan, Gerard M.
    Tahir, Stephen K.
    Tse, Chris
    Wendt, Michael D.
    Xiao, Yu
    Xue, John C.
    Zhang, Haichao
    Humerickhouse, Rod A.
    Rosenberg, Saul H.
    Elmore, Steven W.
    NATURE MEDICINE, 2013, 19 (02) : 202 - 208
12345